Multiple endocrine neoplasia (MEN) is a group of inherited disorders that cause tumors to grow in two or more hormone-producing glands. These glands, part of the endocrine system, regulate everything from metabolism to blood pressure to blood sugar. MEN affects roughly 1 in 30,000 to 1 in 35,000 people, depending on the type, and because it runs in families, a single diagnosis often triggers testing across multiple generations.
There are four recognized types: MEN1, MEN2A, MEN2B, and the more recently identified MEN4. Each type targets different glands, carries different risks, and is caused by a mutation in a different gene. Understanding which type someone has shapes every decision about monitoring and treatment.
MEN1: The “Three P’s”
MEN1 is sometimes called the syndrome of the “three P’s” because it primarily affects the parathyroid glands, the pancreas, and the pituitary gland. It is caused by a mutation in the MEN1 gene, which normally acts as a tumor suppressor. When that gene is faulty, tumors can form in these glands and overproduce hormones, throwing the body’s chemical signaling out of balance.
The most common problem is overactive parathyroid glands. About 95 percent of people with MEN1 develop parathyroid tumors by age 50. These tiny glands in the neck control calcium levels, so when they overproduce their hormone, calcium climbs too high. That can cause kidney stones, bone thinning, fatigue, and confusion.
Around 40 percent of people with MEN1 develop tumors in the pancreas or the upper part of the small intestine. These tumors can release excess hormones like insulin (causing dangerously low blood sugar), gastrin (causing severe stomach ulcers), or glucagon (causing high blood sugar and skin rashes). Some of these tumors are cancerous, and when they spread to the liver, the 10-year survival rate drops to about 50 percent, making them the most serious threat in MEN1.
Nearly one in three people with MEN1 develop a pituitary tumor. The pituitary is a pea-sized gland at the base of the brain that controls growth, reproduction, and other hormonal functions. Tumors here most often overproduce prolactin, which can disrupt menstrual cycles in women or cause sexual dysfunction in men, along with unexpected breast milk production in either sex.
MEN2A: Thyroid Cancer and Adrenal Tumors
MEN2A is the most common subtype of MEN2. Its hallmark is medullary thyroid carcinoma, a cancer that develops in cells of the thyroid gland responsible for producing a hormone that helps regulate calcium. Unlike the more common types of thyroid cancer, medullary thyroid carcinoma can be aggressive and is harder to treat once it spreads.
People with MEN2A may also develop a tumor of the adrenal gland called a pheochromocytoma. The adrenal glands sit on top of the kidneys and produce adrenaline. A pheochromocytoma floods the body with adrenaline, causing episodes of dangerously high blood pressure, rapid heartbeat, headaches, and sweating. Some people with MEN2A also develop overactive parathyroid glands, though this is less common than in MEN1.
A small number of MEN2A families experience additional features: itchy skin lesions on the upper back (a condition called cutaneous lichen amyloidosis) or Hirschsprung disease, a bowel condition in newborns where the large intestine doesn’t function properly.
All forms of MEN2, including MEN2A, are caused by mutations in the RET gene. Unlike the MEN1 gene, which is a tumor suppressor, RET is a proto-oncogene. The mutation essentially locks the gene into an “on” position, continuously signaling cells to grow.
MEN2B: The Rarest and Most Aggressive Form
MEN2B accounts for only about 5 percent of all MEN2 cases, but it is the most aggressive. Everyone with MEN2B develops medullary thyroid carcinoma, and it typically appears at a very young age, sometimes even in infancy. Pheochromocytomas occur in about half of cases. Overactive parathyroid glands, by contrast, are very uncommon in this type.
What sets MEN2B apart visually are its distinctive physical features. Mucosal neuromas, small glistening bumps that form on the lips, tongue, and inside of the cheeks, are often the earliest sign. They can also appear on the eyelids and the surface of the eyes; infants with MEN2B are sometimes unable to produce tears. The lips tend to be thickened and the eyelids prominent.
About 75 percent of people with MEN2B have a tall, thin body type with disproportionately long arms and legs compared to the torso. Spinal curvature abnormalities, loose joints, and other skeletal differences are common. Many also experience chronic digestive problems like constipation, diarrhea, or abdominal bloating because nerve tissue overgrows throughout the intestinal tract, disrupting normal bowel movement.
Because the thyroid cancer in MEN2B is so aggressive, current guidelines recommend preventive removal of the thyroid gland during infancy for children who carry the responsible RET mutations.
MEN4: The Newest Addition
MEN4 was only recently recognized as a distinct syndrome. It looks a lot like MEN1, with overactive parathyroid glands as the most common feature, followed by pituitary tumors and tumors in other endocrine organs. The key difference is the gene involved: MEN4 is caused by mutations in the CDKN1B gene rather than the MEN1 gene.
Compared to MEN1, MEN4 generally appears later in life and seems to follow a milder course. Parathyroid disease in MEN4 shows up at an average age of about 56, versus around 25 in MEN1. None of the reported MEN4 cases so far have had recurrent parathyroid disease after surgery, which is a common frustration in MEN1. Pancreatic tumors also appear to be less frequent in MEN4.
MEN4 is rare. Only about 1.5 to 3.7 percent of patients who look clinically like MEN1 but test negative for a MEN1 gene mutation turn out to carry a CDKN1B mutation instead. Its true prevalence in the general population is still unknown.
How MEN Syndromes Are Detected
Because MEN syndromes are genetic, the diagnosis often starts with a blood relative’s known condition rather than a person’s own symptoms. Genetic testing can identify the specific mutation, and once a mutation is confirmed in a family, at-risk relatives can be tested with a simple blood draw.
For MEN1, screening guidelines recommend starting by age 5 and continuing for life. This includes yearly blood tests measuring calcium, parathyroid hormone, and a panel of hormones related to pituitary and pancreatic function. Imaging of the brain and abdomen is recommended every one to three years to catch tumors early, before they cause symptoms or spread.
For MEN2A, genetic testing of at-risk children is recommended before age 5. If a child carries a RET mutation, preventive thyroid removal is typically performed around age 5 or when the mutation is first identified. Screening for pheochromocytoma is recommended starting at age 11.
For MEN2B, the timeline is compressed because of how aggressive the thyroid cancer can be. Preventive thyroid surgery is recommended in infancy.
What the Diagnosis Means Day to Day
Living with a MEN syndrome means a lifetime of regular monitoring. Even after a tumor is successfully treated, the underlying genetic mutation means new tumors can develop in other glands at any time. For MEN1, the parathyroid glands may need surgery more than once, and pancreatic tumors require ongoing imaging surveillance. For MEN2, people who have had their thyroid removed will take thyroid hormone replacement daily for the rest of their lives, and regular blood tests check for signs that medullary thyroid carcinoma has recurred or that a pheochromocytoma is developing.
The emotional weight of a diagnosis extends beyond the individual. Because MEN syndromes follow an autosomal dominant inheritance pattern, each child of an affected person has a 50 percent chance of inheriting the mutation. That makes family discussions about genetic testing an important, and sometimes difficult, part of managing the condition. Early identification through genetic testing, though, is one of the clearest success stories in hereditary cancer prevention. Children identified as carriers can be monitored or treated preventively, often before any tumor has a chance to cause harm.